Umecrine Cognition gets two US Notices of Allowance on GAMSA compounds
KDventures AB says its portfolio company Umecrine Cognition received two Notices of Allowance from the USPTO for patent applications covering two second-generation GAMSA compound candidates.
STOCKHOLM, Sweden, September 7, 2026. KDventures AB (Nasdaq Stockholm: KDV) today said its portfolio company Umecrine Cognition has received two Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering two second-generation compounds. The company said the Notices of Allowance relate to applications for GAMSA compounds.